| Naslov: | Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : an observational study |
|---|
| Avtorji: | ID Hochmair, Maximilian J (Avtor)
ID Morabito, Alessandro (Avtor)
ID Hao, Desiree (Avtor)
ID Yang, Cheng-Ta (Avtor)
ID Soo, Ross A (Avtor)
ID Yang, James C-H (Avtor)
ID Gucalp, Rasim (Avtor)
ID Halmos, Balazs (Avtor)
ID Wang, Lara (Avtor)
ID Golembesky, Amanda (Avtor)
ID Märten, Angela (Avtor)
ID Čufer, Tanja, Klinika Golnik, Medicinska fakulteta UL (Avtor) |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (2,39 MB)
MD5: 3F2D8BA9D4F2488B02256DB856ABFA69
 URL - Izvorni URL, za dostop obiščite https://www.futuremedicine.com/doi/full/10.2217/fon-2018-0711?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed#
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
|
|---|
| Povzetek: | Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive disease following first-line afatinib and started osimertinib treatment [>/=]10 months prior to data entry. Primary outcome was time on treatment. Results: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors. |
|---|
| Ključne besede: | lung neoplasms -- therapy, non-small-cell lung cancer, afatinib, osimertinib, epidermal growth factor receptor, EGFR, observational study |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Kraj izida: | Velika Britanija |
|---|
| Založnik: | Future Medicine Ltd |
|---|
| Leto izida: | 2018 |
|---|
| Št. strani: | str. 2861-2874 |
|---|
| Številčenje: | Vol. 14, no. 27 |
|---|
| PID: | 20.500.12556/DiRROS-12623  |
|---|
| UDK: | 616-006 |
|---|
| ISSN pri članku: | 1744-8301 |
|---|
| DOI: | 10.2217/fon-2018-0711 |
|---|
| COBISS.SI-ID: | 2048432753 |
|---|
| Avtorske pravice: | 2018 Maximilian Hochmair |
|---|
| Opomba: | Soavtorji: Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A Soo, James C-H Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Amanda Golembesky, Angela Märten & Tanja Cufer;
Nasl. z nasl. zaslona;
Opis vira z dne 9. 1. 2019;
|
|---|
| Datum objave v DiRROS: | 09.11.2020 |
|---|
| Število ogledov: | 1872 |
|---|
| Število prenosov: | 1086 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
